Unraveling the Extracellular Matrix and its Remodelling to Improve the Understanding of Pharmacological Effects in Patients with Pulmonary Fibrosis

  • Association between ECM remodeling biomarkers and IPF severity/progression
  • Reduction of ECM biomarkers in IPF/ILD clinical trials and link to lung function improvement
  • Fibrogenesis biomarkers in preclinical models to support early drug development